Gabriel Roybal

Director Of Cs, Heor-rwe | Clinical Development | Medical Affairs | Market Accesss at Komodo Health

Gabriel Roybal, PhD, has held various roles throughout their work experience. Gabriel is currently the Director of Real-world Evidence and Health Economics Outcomes Research at Komodo Health, where they lead a team that delivers healthcare data insights to Pharma and Biotech companies. Gabriel also previously served as the Director of Life Sciences at Komodo Health, where they led a team focused on delivering life science data insights to the same industry.

Prior to their time at Komodo Health, Gabriel worked at Science Exchange, where they held positions such as Director of Business Development, Director of Research and Development, and Senior Scientist | Account Executive. In these roles, they were responsible for engaging with stakeholders, facilitating communication, and managing projects.

Before joining Science Exchange, Gabriel held positions at TapGenes as the VP of Business Development and Growth Strategies, and at grouphub.io as the Founder and Chief Marketing Officer. Gabriel also worked at UCSF as an NIH IRACDA Scholar in Science Postdoctoral Fellow, and at UC Santa Cruz as a National Human Genome Research Institute Scholar and PhD Candidate.

Overall, Gabriel Roybal, PhD, has a diverse background in healthcare, business development, and research, and has contributed to various aspects of the industry throughout their career.

Gabriel Roybal, PhD holds a B.A. in Biological Basis of Behavior and Psychology from the University of Pennsylvania. Gabriel further pursued their education at the University of California, Santa Cruz, where they obtained a Ph.D. in Molecular, Cell and Developmental Biology. Additionally, they have obtained a certification in HIPAA Security from HIPAA Training.

Links

Previous companies

UC Santa Cruz logo
grouphub.io logo
TapGenes logo
Science Exchange logo

Peers

View in org chart

Timeline

  • Director Of Cs, Heor-rwe | Clinical Development | Medical Affairs | Market Accesss

    February 1, 2024 - present

  • Director, Real-world Evidence And Health Economics Outcomes Research

    February, 2022

  • Director, Life Sciences

    April, 2020